![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: EGFR |
Gene summary for EGFR |
![]() |
Gene information | Species | Human | Gene symbol | EGFR | Gene ID | 1956 |
Gene name | epidermal growth factor receptor | |
Gene Alias | ERBB | |
Cytomap | 7p11.2 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q504U8 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1956 | EGFR | CA_HPV_1 | Human | Cervix | CC | 2.14e-07 | -2.95e-01 | 0.0264 |
1956 | EGFR | CA_HPV_3 | Human | Cervix | CC | 1.15e-12 | 3.49e-01 | 0.0414 |
1956 | EGFR | CCI_1 | Human | Cervix | CC | 1.13e-21 | 2.02e+00 | 0.528 |
1956 | EGFR | CCI_2 | Human | Cervix | CC | 4.65e-04 | 1.18e+00 | 0.5249 |
1956 | EGFR | CCI_3 | Human | Cervix | CC | 8.86e-25 | 1.67e+00 | 0.516 |
1956 | EGFR | Tumor | Human | Cervix | CC | 1.95e-06 | 3.01e-01 | 0.1241 |
1956 | EGFR | sample3 | Human | Cervix | CC | 1.78e-19 | 4.03e-01 | 0.1387 |
1956 | EGFR | T3 | Human | Cervix | CC | 1.92e-12 | 3.21e-01 | 0.1389 |
1956 | EGFR | HTA11_3410_2000001011 | Human | Colorectum | AD | 4.41e-08 | -4.24e-01 | 0.0155 |
1956 | EGFR | HTA11_347_2000001011 | Human | Colorectum | AD | 3.34e-10 | 6.12e-01 | -0.1954 |
1956 | EGFR | HTA11_411_2000001011 | Human | Colorectum | SER | 5.78e-04 | 7.22e-01 | -0.2602 |
1956 | EGFR | HTA11_99999970781_79442 | Human | Colorectum | MSS | 6.02e-13 | -4.52e-01 | 0.294 |
1956 | EGFR | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.95e-07 | -4.41e-01 | 0.3859 |
1956 | EGFR | HTA11_99999974143_84620 | Human | Colorectum | MSS | 5.21e-27 | -6.79e-01 | 0.3005 |
1956 | EGFR | F007 | Human | Colorectum | FAP | 3.80e-04 | -3.45e-01 | 0.1176 |
1956 | EGFR | A015-C-203 | Human | Colorectum | FAP | 7.86e-35 | -4.60e-01 | -0.1294 |
1956 | EGFR | A015-C-204 | Human | Colorectum | FAP | 1.06e-05 | -3.33e-01 | -0.0228 |
1956 | EGFR | A014-C-040 | Human | Colorectum | FAP | 1.30e-03 | -3.14e-01 | -0.1184 |
1956 | EGFR | A002-C-201 | Human | Colorectum | FAP | 1.67e-18 | -5.41e-01 | 0.0324 |
1956 | EGFR | A001-C-119 | Human | Colorectum | FAP | 1.90e-10 | -6.44e-01 | -0.1557 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001603210 | Cervix | CC | viral process | 109/2311 | 415/18723 | 5.40e-15 | 6.46e-12 | 109 |
GO:004217610 | Cervix | CC | regulation of protein catabolic process | 104/2311 | 391/18723 | 9.39e-15 | 9.36e-12 | 104 |
GO:004206010 | Cervix | CC | wound healing | 109/2311 | 422/18723 | 1.84e-14 | 1.57e-11 | 109 |
GO:001905810 | Cervix | CC | viral life cycle | 87/2311 | 317/18723 | 2.20e-13 | 1.20e-10 | 87 |
GO:00085446 | Cervix | CC | epidermis development | 83/2311 | 324/18723 | 3.91e-11 | 8.54e-09 | 83 |
GO:00435884 | Cervix | CC | skin development | 71/2311 | 263/18723 | 8.04e-11 | 1.46e-08 | 71 |
GO:000697910 | Cervix | CC | response to oxidative stress | 102/2311 | 446/18723 | 2.99e-10 | 4.36e-08 | 102 |
GO:190382910 | Cervix | CC | positive regulation of cellular protein localization | 72/2311 | 276/18723 | 3.20e-10 | 4.46e-08 | 72 |
GO:007265910 | Cervix | CC | protein localization to plasma membrane | 73/2311 | 284/18723 | 4.95e-10 | 6.73e-08 | 73 |
GO:005212610 | Cervix | CC | movement in host environment | 52/2311 | 175/18723 | 7.03e-10 | 8.76e-08 | 52 |
GO:004440910 | Cervix | CC | entry into host | 47/2311 | 151/18723 | 8.45e-10 | 1.03e-07 | 47 |
GO:005170110 | Cervix | CC | biological process involved in interaction with host | 57/2311 | 203/18723 | 1.18e-09 | 1.41e-07 | 57 |
GO:007149610 | Cervix | CC | cellular response to external stimulus | 78/2311 | 320/18723 | 1.82e-09 | 1.98e-07 | 78 |
GO:00506737 | Cervix | CC | epithelial cell proliferation | 98/2311 | 437/18723 | 2.01e-09 | 2.15e-07 | 98 |
GO:00160557 | Cervix | CC | Wnt signaling pathway | 98/2311 | 444/18723 | 4.82e-09 | 4.65e-07 | 98 |
GO:00321035 | Cervix | CC | positive regulation of response to external stimulus | 95/2311 | 427/18723 | 5.44e-09 | 5.03e-07 | 95 |
GO:004671810 | Cervix | CC | viral entry into host cell | 44/2311 | 144/18723 | 5.47e-09 | 5.03e-07 | 44 |
GO:01987387 | Cervix | CC | cell-cell signaling by wnt | 98/2311 | 446/18723 | 6.16e-09 | 5.58e-07 | 98 |
GO:004440310 | Cervix | CC | biological process involved in symbiotic interaction | 71/2311 | 290/18723 | 7.94e-09 | 6.98e-07 | 71 |
GO:003367410 | Cervix | CC | positive regulation of kinase activity | 101/2311 | 467/18723 | 8.66e-09 | 7.22e-07 | 101 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0522541 | Lung | MIAC | Hepatocellular carcinoma | 20/507 | 168/8465 | 2.44e-03 | 2.16e-02 | 1.56e-02 | 20 |
hsa052144 | Lung | MIAC | Glioma | 11/507 | 75/8465 | 4.77e-03 | 3.49e-02 | 2.52e-02 | 11 |
hsa051654 | Lung | MIAC | Human papillomavirus infection | 32/507 | 331/8465 | 4.78e-03 | 3.49e-02 | 2.52e-02 | 32 |
hsa0481042 | Lung | MIAC | Regulation of actin cytoskeleton | 24/507 | 229/8465 | 5.17e-03 | 3.58e-02 | 2.59e-02 | 24 |
hsa0517173 | Lung | MIAC | Coronavirus disease - COVID-19 | 79/507 | 232/8465 | 4.83e-40 | 7.02e-38 | 5.08e-38 | 79 |
hsa0452072 | Lung | MIAC | Adherens junction | 27/507 | 93/8465 | 2.36e-12 | 2.29e-10 | 1.66e-10 | 27 |
hsa0520571 | Lung | MIAC | Proteoglycans in cancer | 31/507 | 205/8465 | 1.45e-06 | 9.39e-05 | 6.79e-05 | 31 |
hsa0401571 | Lung | MIAC | Rap1 signaling pathway | 29/507 | 210/8465 | 1.94e-05 | 9.40e-04 | 6.80e-04 | 29 |
hsa0152151 | Lung | MIAC | EGFR tyrosine kinase inhibitor resistance | 15/507 | 79/8465 | 5.68e-05 | 2.07e-03 | 1.49e-03 | 15 |
hsa045107 | Lung | MIAC | Focal adhesion | 27/507 | 203/8465 | 7.28e-05 | 2.35e-03 | 1.70e-03 | 27 |
hsa049217 | Lung | MIAC | Oxytocin signaling pathway | 22/507 | 154/8465 | 1.18e-04 | 3.11e-03 | 2.25e-03 | 22 |
hsa0492851 | Lung | MIAC | Parathyroid hormone synthesis, secretion and action | 17/507 | 106/8465 | 1.69e-04 | 3.51e-03 | 2.54e-03 | 17 |
hsa0513153 | Lung | MIAC | Shigellosis | 29/507 | 247/8465 | 3.64e-04 | 7.06e-03 | 5.11e-03 | 29 |
hsa0516353 | Lung | MIAC | Human cytomegalovirus infection | 27/507 | 225/8465 | 4.07e-04 | 7.19e-03 | 5.20e-03 | 27 |
hsa0521351 | Lung | MIAC | Endometrial cancer | 11/507 | 58/8465 | 5.55e-04 | 7.61e-03 | 5.51e-03 | 11 |
hsa0521551 | Lung | MIAC | Prostate cancer | 15/507 | 97/8465 | 6.02e-04 | 7.61e-03 | 5.51e-03 | 15 |
hsa040107 | Lung | MIAC | MAPK signaling pathway | 32/507 | 302/8465 | 1.12e-03 | 1.36e-02 | 9.81e-03 | 32 |
hsa0401251 | Lung | MIAC | ErbB signaling pathway | 13/507 | 85/8465 | 1.52e-03 | 1.58e-02 | 1.14e-02 | 13 |
hsa0522551 | Lung | MIAC | Hepatocellular carcinoma | 20/507 | 168/8465 | 2.44e-03 | 2.16e-02 | 1.56e-02 | 20 |
hsa052145 | Lung | MIAC | Glioma | 11/507 | 75/8465 | 4.77e-03 | 3.49e-02 | 2.52e-02 | 11 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
AREG | EGFR | AREG_EGFR | EGF | Breast | ADJ |
HBEGF | EGFR | HBEGF_EGFR | EGF | Breast | ADJ |
AREG | EGFR | AREG_EGFR | EGF | Breast | DCIS |
AREG | EGFR_ERBB2 | AREG_EGFR_ERBB2 | EGF | Breast | DCIS |
HBEGF | EGFR | HBEGF_EGFR | EGF | Breast | DCIS |
HBEGF | EGFR_ERBB2 | HBEGF_EGFR_ERBB2 | EGF | Breast | DCIS |
EREG | EGFR | EREG_EGFR | EGF | Breast | DCIS |
EREG | EGFR_ERBB2 | EREG_EGFR_ERBB2 | EGF | Breast | DCIS |
AREG | EGFR | AREG_EGFR | EGF | Breast | Healthy |
HBEGF | EGFR | HBEGF_EGFR | EGF | Breast | Healthy |
EREG | EGFR | EREG_EGFR | EGF | Breast | Healthy |
AREG | EGFR | AREG_EGFR | EGF | Breast | Precancer |
HBEGF | EGFR | HBEGF_EGFR | EGF | Breast | Precancer |
EREG | EGFR | EREG_EGFR | EGF | Breast | Precancer |
AREG | EGFR | AREG_EGFR | EGF | Cervix | ADJ |
HBEGF | EGFR | HBEGF_EGFR | EGF | Cervix | ADJ |
AREG | EGFR | AREG_EGFR | EGF | Cervix | CC |
AREG | EGFR_ERBB2 | AREG_EGFR_ERBB2 | EGF | Cervix | CC |
HBEGF | EGFR | HBEGF_EGFR | EGF | Cervix | CC |
HBEGF | EGFR_ERBB2 | HBEGF_EGFR_ERBB2 | EGF | Cervix | CC |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EGFR | SNV | Missense_Mutation | novel | c.941N>G | p.Asp314Gly | p.D314G | P00533 | protein_coding | tolerated(0.26) | benign(0.031) | TCGA-A2-A4S3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
EGFR | SNV | Missense_Mutation | rs532655845 | c.439G>A | p.Ala147Thr | p.A147T | P00533 | protein_coding | deleterious(0.02) | benign(0.027) | TCGA-A7-A6VX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR |
EGFR | SNV | Missense_Mutation | c.3151N>A | p.Asp1051Asn | p.D1051N | P00533 | protein_coding | tolerated(0.6) | benign(0.001) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
EGFR | SNV | Missense_Mutation | c.1577G>C | p.Cys526Ser | p.C526S | P00533 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-AR-A0TV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
EGFR | SNV | Missense_Mutation | c.340G>A | p.Glu114Lys | p.E114K | P00533 | protein_coding | deleterious(0.04) | benign(0.012) | TCGA-AR-A2LR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
EGFR | SNV | Missense_Mutation | rs201717672 | c.3602N>T | p.Ala1201Val | p.A1201V | P00533 | protein_coding | deleterious(0.01) | benign(0.284) | TCGA-B6-A0RQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EGFR | SNV | Missense_Mutation | rs138847501 | c.769G>A | p.Glu257Lys | p.E257K | P00533 | protein_coding | deleterious(0.01) | benign(0.206) | TCGA-BH-A18U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
EGFR | SNV | Missense_Mutation | c.2540N>A | p.Thr847Lys | p.T847K | P00533 | protein_coding | deleterious(0) | possibly_damaging(0.555) | TCGA-C8-A1HG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
EGFR | SNV | Missense_Mutation | c.340G>A | p.Glu114Lys | p.E114K | P00533 | protein_coding | deleterious(0.04) | benign(0.012) | TCGA-D8-A1JF-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
EGFR | SNV | Missense_Mutation | rs121913465 | c.2303N>T | p.Ser768Ile | p.S768I | P00533 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-GM-A2DD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1956 | EGFR | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TYROSINE KINASE, DRUG RESISTANCE | AMG 595 | |||
1956 | EGFR | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TYROSINE KINASE, DRUG RESISTANCE | inhibitor | 249565586 | POZIOTINIB | |
1956 | EGFR | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TYROSINE KINASE, DRUG RESISTANCE | inhibitor | CHEMBL1201827 | PANITUMUMAB | |
1956 | EGFR | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TYROSINE KINASE, DRUG RESISTANCE | inhibitor | 385612228 | ||
1956 | EGFR | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TYROSINE KINASE, DRUG RESISTANCE | gefitinib | GEFITINIB | 18681783,17375033,22370314,14990633,16467544,16377102,17317677,14990632,18784101,17020982,19473722,21921847,16912157,19589612,20573926,16258541,19692680,22581822,17192902,16203769,16257339,17429313,18000659,17085664,18003960,19381876,17473659,15897572,22215752,26490356,23022519,21900837,20038723,16865253,11255078,17285735,15118073,20022809,16115929,19339720,18316547,19201048,22760226,16204011,16956694,17597605,12648464,21233402,18992959,22237259,22594511 | |
1956 | EGFR | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TYROSINE KINASE, DRUG RESISTANCE | Pyrrolo[2,3-d]pyrimidine derivative 24 | |||
1956 | EGFR | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TYROSINE KINASE, DRUG RESISTANCE | INC280 | CAPMATINIB | 28783719 | |
1956 | EGFR | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TYROSINE KINASE, DRUG RESISTANCE | inhibitor | 363894206 | ALLITINIB | |
1956 | EGFR | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TYROSINE KINASE, DRUG RESISTANCE | inhibitor | CHEMBL422872 | AZD-4769 | |
1956 | EGFR | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TYROSINE KINASE, DRUG RESISTANCE | inhibitor | 315661259 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 |